Expresson data from lncRNA LINC01929 knockdown in MCF7 and MDA-MB-231 breast cancer cell lines

LncRNA LINC01929 was knocked down using anti-LINC01929 antisense oligonucleotides (ASOs) in the ER+ breast cancer cell line MCF7 and the triple-negative breast cancer cell line MDA-MB-231. To investigate the impact of lncRNA LINC01929 on the transcriptome of ER+ and triple-negative breast cancer, microarray analyses were conducted on MCF7 and MDA-MB-231 cell lines. Cells were treated with either control ASO or anti-LINC01929 ASO for 48 hours. Following the ASO treatment, the cells were collected and preserved in TRIzol reagent for subsequent RNA purification. The purified RNA samples were then sent to The Centre for Applied Genomics (TCAG), located at The Hospital for Sick Children in Toronto, Canada. The RNA samples underwent reverse transcription into complementary DNA (cDNA) and were subsequently hybridized to the Affymetrix Human Gene 2.0 ST microarray platform. The collected data was initially obtained in raw CEL format and subsequently processed using the Transcriptome Analysis Console (Affymetrix).